/BBOT
BBOT Stock - BridgeBio Oncology Therapeutics Inc.
Healthcare|BiotechnologyNASDAQ
$12.52+3.86%
+$0.47 (+3.86%) • Dec 19
84
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.74
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+59.7%upside
Target: $19.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BBOT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.39 – $12.65
TARGET (TP)$20.00
STOP LOSS$11.52
RISK/REWARD1:7.5
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.08
52W High$14.87
52W Low$8.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Income | $-80,863,000 | $-64,771,000 | $-3,520 | $-43,357 |
| Net Income | $-74,275,000 | $-64,699,000 | $-3,520 | $-43,357 |
| Net Margin | N/A | N/A | N/A | N/A |
| EPS | $0.46 | $-0.00 | $0.00 | $-0.00 |
Company Overview
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$23
Average Target
↑ 85.7% Upside
Now
$20
Low
$23
Average
$27
High
Based on 4 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 5th 2025 | Morgan Stanley | Initiation | Overweight | $20 |
| September 17th 2025 | Leerink Partners | Initiation | Outperform | $25 |
| September 15th 2025 | H.C. Wainwright | Initiation | Buy | $27 |
| August 15th 2025 | Piper Sandler | Initiation | Overweight | $21 |
Earnings History & Surprises
BBOTBeat Rate
0%
Last 1 quarters
Avg Surprise
-151.2%
EPS vs Estimate
Beats / Misses
0/1
Last 12 quarters
Latest EPS
$-1.03
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
-151.2%
$-1.03vs$-0.41
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 11, 2026 | $-0.47 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.41 | $-1.03 | -151.2% | ✗ MISS |
Q3 2025 | Aug 1, 2025 | — | $0.04 | — | — |
Q2 2025 | May 15, 2025 | — | $-0.02 | — | — |
Q1 2025 | Mar 11, 2025 | — | $0.12 | — | — |
Q4 2024 | Nov 14, 2024 | — | $0.10 | — | — |
Q3 2024 | Aug 14, 2024 | — | $0.09 | — | — |
Q2 2024 | May 15, 2024 | — | $0.08 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Latest News
Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
📈 PositiveBenzinga•Dec 11, 2025, 02:28 PM
BBOT To Present Data On BBO-10203 At San Antonio Breast Cancer Symposium Dec. 12
➖ NeutralBenzinga•Dec 10, 2025, 09:12 PM
BridgeBio Oncology Therapeutics shares are trading higher after Morgan Stanley initiated coverage on the stock with an Overweight rating and announced a $20 price target.
📈 PositiveBenzinga•Dec 5, 2025, 06:29 PM
Morgan Stanley Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $20
📈 PositiveBenzinga•Dec 5, 2025, 03:22 PM
Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target
📈 PositiveBenzinga•Nov 25, 2025, 02:08 PM
Oppenheimer Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $22
➖ NeutralBenzinga•Nov 13, 2025, 06:08 PM
BridgeBio Oncology Q3 EPS $(1.03) Misses $(0.40) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 09:28 PM
Reported Saturday, BridgeBio Oncology Therapeutics Presents Preclinical Data Showing BBO-10203 Inhibits KRAS-Mutant Tumor Growth Without Inducing Hyperglycemia
📈 PositiveBenzinga•Oct 27, 2025, 06:52 AM
BridgeBio Presents New Preclinical Data On BBO-11818 Demonstrating Potential As Potent panKRAS Inhibitor Targeting Mutant KRAS In Both ON And OFF States, With Selectivity Over HRAS And NRAS, At 2025 AACR-NCI-EORTC
📈 PositiveBenzinga•Oct 23, 2025, 08:13 PM
Bridgebio Oncology Therapeutics Announces It Will Present Posters At The 2025 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics October 22–26, 2025, In Boston, Massachusetts
📈 PositiveBenzinga•Oct 13, 2025, 08:09 PM
BridgeBio started at outperform at Leerink on 'differentiated' oncology platform
📈 PositiveSeeking Alpha•Sep 17, 2025, 06:35 PM
BridgeBio Oncology Therapeutics shares are trading higher. Leerink Partners Initiated coverage on the stock with an Outperform rating and a price target of $25.
📈 PositiveBenzinga•Sep 17, 2025, 06:33 PM
Leerink Partners Initiates Coverage On BridgeBio Oncology with Outperform Rating, Announces Price Target of $25
📈 PositiveBenzinga•Sep 17, 2025, 12:21 PM
HC Wainwright & Co. Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $27
📈 PositiveBenzinga•Sep 15, 2025, 11:58 AM
Oppenheimer Initiates Coverage On BridgeBio Oncology with Outperform Rating, Announces Price Target of $23
📈 PositiveBenzinga•Sep 4, 2025, 12:52 PM
BridgeBio Oncology Therapeutics shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $25.
📈 PositiveBenzinga•Aug 18, 2025, 07:25 PM
Wedbush Initiates Coverage On BridgeBio Oncology with Outperform Rating, Announces Price Target of $25
📈 PositiveBenzinga•Aug 18, 2025, 02:29 PM
Frequently Asked Questions about BBOT
What is BBOT's current stock price?
BridgeBio Oncology Therapeutics Inc. (BBOT) is currently trading at $12.52 per share. The stock has moved +3.86% today.
What is the analyst price target for BBOT?
The average analyst price target for BBOT is $20.00, based on 1 analyst.
What sector is BridgeBio Oncology Therapeutics Inc. in?
BridgeBio Oncology Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BBOT's market cap?
BridgeBio Oncology Therapeutics Inc. has a market capitalization of $1.00 billion, making it a small-cap company.
Does BBOT pay dividends?
No, BridgeBio Oncology Therapeutics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANAB
AnaptysBio, Inc.
$49.08
Mkt Cap: $1.4B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
MNMD
Mind Medicine (MindMed) Inc.
$12.70
Mkt Cap: $1.0B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
OCS
Oculis Holding AG
$21.25
Mkt Cap: $1.1B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to BBOT for comparison